Cibus Inc (CBUS)

Currency in USD
1.90
+0.04(+2.15%)
Closed·
1.93+0.03(+1.58%)
·
CBUS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.842.04
52 wk Range
1.093.40
Key Statistics
Prev. Close
1.9
Open
1.84
Day's Range
1.84-2.04
52 wk Range
1.09-3.4
Volume
280.07K
Average Volume (3m)
225.68K
1-Year Change
-23.3871%
Book Value / Share
0.96
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CBUS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.40
Upside
+657.89%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Cibus Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Cibus Inc Company Profile

Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products. It focuses on trait productivity in the productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients, which enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was founded in 2001 and is headquartered in San Diego, California.

Cibus Inc Earnings Call Summary for Q3/2025

  • Cibus (CBUS) reported Q3 2025 EPS of -$0.44, missing forecasts of -$0.30, with revenue falling to $615,000 from $1.7 million year-over-year; shares dropped 8.89% to $1.23 post-announcement.
  • Despite financial setbacks, the company reduced operating expenses by nearly $5 million in the first nine months of 2025 and maintained $23.9 million in cash and cash equivalents.
  • CEO Peter Beetham positioned the company as 'a coiled spring at the forefront' of the gene-editing revolution, emphasizing strategic innovations despite current challenges.
  • Cibus forecasts initial biofragrance revenues in Q4 2025 and commercial launches of RISE traits from 2027, with herbicide-tolerant traits expected to be primary revenue drivers.
  • Management guidance remains cautious, focusing on continued cost management while navigating revenue decline, potential market saturation, and regulatory challenges in global markets.
Last Updated: 2025-11-13, 06:18 p/m
Read Full Transcript

Compare CBUS to Peers and Sector

Metrics to compare
CBUS
Peers
Sector
Relationship
P/E Ratio
−0.9x−1.0x−0.6x
PEG Ratio
−0.01−0.040.00
Price/Book
2.0x0.3x2.6x
Price / LTM Sales
27.2x31.1x3.4x
Upside (Analyst Target)
-522.4%41.5%
Fair Value Upside
Unlock23.1%5.5%Unlock

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 14.40
(+657.89% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord Genuity
Buy15.00+689.47%17.50MaintainJun 05, 2025
Canaccord Genuity
Buy17.50+821.05%18.00MaintainMay 12, 2025
Canaccord Genuity
Buy18.00+847.37%20.00MaintainJan 21, 2025

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-0.44 / -0.30
Revenue / Forecast
620.00K / --
EPS Revisions
Last 90 days

CBUS Income Statement

People Also Watch

0.33
FBLG
0.00%
13.76
JANX
+0.29%
5.4100
BBGI
-10.28%
1.700
XAIR
-1.16%

FAQ

What Is the Cibus (CBUS) Stock Price Today?

The Cibus stock price today is 1.90

What Stock Exchange Does Cibus Trade On?

Cibus is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Cibus?

The stock symbol for Cibus is "CBUS."

What Is the Cibus Market Cap?

As of today, Cibus market cap is 103.02M.

What Is Cibus's Earnings Per Share (TTM)?

The Cibus EPS (TTM) is -3.04.

When Is the Next Cibus Earnings Date?

Cibus will release its next earnings report on Nov 13, 2025.

From a Technical Analysis Perspective, Is CBUS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Cibus Stock Split?

Cibus has split 2 times.

How Many Employees Does Cibus Have?

Cibus has 158 employees.

What is the current trading status of Cibus (CBUS)?

As of Jan 20, 2026, Cibus (CBUS) is trading at a price of 1.90, with a previous close of 1.90. The stock has fluctuated within a day range of 1.84 to 2.04, while its 52-week range spans from 1.09 to 3.40.

What Is Cibus (CBUS) Price Target According to Analysts?

The average 12-month price target for Cibus is USD14.40, with a high estimate of USD25 and a low estimate of USD1.6. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +657.89% Upside potential.

What Is the CBUS After Hours Price?

CBUS's last after hours stock price is 1.93, the stock has decreased by 0.03, or 1.58%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.